Company news
Innoviva, Inc. news in 2025
Innoviva, Inc.'s news releases, calls and decks from 2025, newest first.
U.S. FDA Approves NUZOLVENCE(R) (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
December 15, 2025
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
December 11, 2025
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
December 10, 2025
Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference
November 24, 2025
Beacon Biosignals Raises $86M to Accelerate AI-Driven Insights into Brain Health
November 13, 2025
Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress
November 4, 2025
Antheia Appoints Eric d'Esparbes as Chief Financial Officer
October 21, 2025
Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025
October 19, 2025
Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025
October 6, 2025
Innoviva to Participate in Upcoming Investor Conferences
August 25, 2025
Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award
August 12, 2025
Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress
August 6, 2025
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
June 11, 2025
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
June 9, 2025
ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections
May 19, 2025
Innoviva Reports First Quarter 2025 Financial Results, Highlights Recent Company Progress
May 8, 2025
Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress
May 6, 2025
Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference
March 4, 2025
Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress
February 25, 2025
Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 5, 2025